Vascular Markers
    EP111 Rabbit Monoclonal

    In prostate cancer, the ERG gene locus may undergo a chromosomal translocation with the androgen-regulated transmembrane protease serine 2 (TMPRSS2) gene, resulting in the expression of an TMPRSS2-ERG oncoprotein; a new diagnostic marker of prostate cancer. The TMPRSS2-ERG fusion has been found to be the most common proto-oncogene present in prostate cancers, occurring in about 50% of cases. Molecular methods (FISH, bDNA) have shown a strong correlation between TMRPSS2-ERG rearrangement status and ERG expression, as detected by IHC. ERG oncoprotein expression has been shown to be a highly specific marker for prostate cancer. Given the lack of ERG expression in a wide variety of normal epithelial tissues and tumors, and its robust presence in prostatic adenocarcinoma, detection of ERG by IHC is a valuable tool for diagnosing prostate cancer or determining prostatic origin. ERG is also high expressed in vascular endothelial cells, making it a very specific marker for vascular tumors.

    Species Reactivity:Humans; others not tested
    Known Applications:Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
    Supplied As:Buffer with protein carrier and preservative
    Storage:Store at 2ºC to 8ºC
    Control:Prostate adenocarcinoma
    Immunogen:A synthetic peptide corresponding to residues on the C-terminus in human ERG protein
    Ordering Information
    Classification IVD
    Catalogue Number Z2280RL
    Classification IVD
    Catalogue Number Z2280RL
    Package Inserts
    IFU-ERG EP111
    Regulatory Notice
    Product classification varies based on regulations of individual countries. Please contact your local distributor for more information. Products labeled as ASR or RUO in the US might be available as IVD or RUO in respective countries.